Case ReportUterine adenofibroma and endometrial stromal sarcoma associated with tamoxifen therapy: MR findings
Section snippets
Case 1
A 74-year-old woman, who was postmenopausal, had been taking tamoxifen 20 mg daily for 3 years for breast cancer. She was asymptomatic, but on routine ultrasound a mass was detected in the uterus, for which she was referred for MRI examination. Routine hematological, biochemical and tumor marker determinations revealed no particular abnormalities. On pelvic examination, the uterus was slightly enlarged, while the cervix appeared normal. On sagittal T2-weighted MR images, a heterogeneously
Discussion
Tamoxifen, a nonsteroid triphenylethylene derivative that is structurally related to the synthetic estrogen diethylstilbestrol [7], is the most widely prescribed anticancer agent [8]. Paradoxically, tamoxifen acts as an estrogen agonist in the gynecological tract, including the endometrium, and is associated with an increased frequency of proliferative endometrial lesions, including endometrial neoplasm [9]. In 89 cases receiving tamoxifen therapy, uterine adenofibroma was reported in only a
Kazumasa Hayasaka is the director of Radiology department, National Center for Geriatrics and Gerontology, Japan.
References (16)
Pappilary adenofibroma of the uterine cervix
Am J Obstet Gynecol
(1971)- et al.
Adenofibroma of the uterus: multiple recurrence following wide local excision
Gynecol Oncol
(1990) Uterine sarcomas: histogenesis and taxonomy
Ann N Y Acad Sci
(1959)- et al.
Papillary cystadenofibroma of endometrium: a histochemical and ultrastructual study
Cancer
(1975) - et al.
Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases
Cancer
(1981) - et al.
Endometrial stromal sarcoma
Surg Gynecol Obstet
(1965) Endometrial changes with chronic tamoxifen use
Cur Opin Obstet Gynecol
(1979)- et al.
Adjuvant tamoxifen: how long before we know how long?
Br Med J
(1998)
Cited by (10)
Sex hormones and related compounds, including hormonal contraceptives
2009, Side Effects of Drugs AnnualCitation Excerpt :Since the first reported case of tamoxifen-associated related uterine sarcoma in 1988, 68 more cases have described, 4 recent instances now being reported (96AR, 97A). A Japanese group has stressed the particular value of MRI in diagnosing this complication in the context of another case (98A). Although some of these investigators have pointed out that the low incidence of uterine sarcomas makes it difficult to establish a firm relation to the drug, it seems that a dose of 20 mg/day of tamoxifen over 1 year could be enough to promote the development of sarcomas in certain users.
High-grade endometrial stromal sarcoma following tamoxifen treatment
2008, Gynecologic OncologyEndometrial Adenofibroma in a Patient Receiving Toremifene: A Case Report
2024, Current Medical ImagingEndometrial adenofibroma; A Case Report
2019, Middle East Journal of Rehabilitation and Health StudiesUterine sarcomas and atypical smooth-muscle tumors: Clinic, diagnostics and appropriate surgical therapy
2017, Hysterectomy: A Comprehensive Surgical Approach
Kazumasa Hayasaka is the director of Radiology department, National Center for Geriatrics and Gerontology, Japan.
Kazuo Morita is the director of Obstetrics and Gynecology department, Akiru Municipal General Hospital, Japan.
Tomoya Saitoh is an assistant of Radiology department, Nihon University School of Medicine, Japan.
Yoshiaki Tanaka is professor of Radiology department, Nihon University School of Medicine, Japan.